54207-6 |
Coagulation surface induced.factor substitution^immediately after addition of factor V depleted plasma |
Time |
PPP |
Pt |
Qn |
Coag |
|
ACTIVE |
aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor V depleted plasma |
|
MIN |
DefinitionDescription |
|
|
s |
APC-1 35 secoonds. |
|
|
|
|
|
COAG |
|
54207-6 |
|
Coag |
|
|
Observation |
|
|
|
0 |
aPTT imm FV DP PPP |
|
|
|
N |
|
Activated partial thromboplastin time; aPTT; aPTT correction study; Clot; Clottable; Coag; Coagulation assay; Fac; Fact; Factor 5; FV; Hematology; Heme; imm FV DP; Immediatedly after 1:1 addition of; Little(A)PTT; Mixing studies; Partial Thromboplastin Time; Plas; Platelet poor plasma; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube |
2.52 |
2.27 |
|
|
|
|
|
|
|
s |
|
|
|
0 |
54208-4 |
Coagulation surface induced.factor substitution^immediately after addition of factor V depleted plasma+APC |
Time |
PPP |
Pt |
Qn |
Coag |
|
ACTIVE |
aPTT.factor substitution in Platelet poor plasma by Coagulation assay --immediately after addition of factor V depleted plasma+APC |
|
MIN |
DefinitionDescription |
|
|
s |
APC-2 78 seconds. |
|
|
|
|
|
COAG |
|
54208-4 |
|
Coag |
|
|
Observation |
|
|
|
0 |
aPTT imm FV DP+APC PPP |
|
|
|
N |
|
Activated partial thromboplastin time; aPTT; aPTT correction study; Clot; Clottable; Coag; Coagulation assay; Fac; Fact; Factor 5; FV; Hematology; Heme; imm FV DP; imm FV DP+APC; Immediatedly after 1:1 addition of; Little(A)PTT; Mixing studies; Partial Thromboplastin Time; Plas; Platelet poor plasma; Point in time; PTT; QNT; Quan; Quant; Quantitative; Random; Surf; Tilt tube |
2.52 |
2.27 |
|
|
|
|
|
|
|
s |
|
|
|
0 |
54209-2 |
Hemoglobin C-Harlem/Hemoglobin.total |
MFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Hemoglobin C - Harlem/Hemoglobin.total in Blood |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
54209-2 |
|
|
|
|
Both |
|
|
|
0 |
Hgb C-Harlem MFr Bld |
|
|
|
N |
|
Blood; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hemoglobin C - Harlam; Hgb; Hgb C; Hgb C-Harlem; Mass Fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; WB; Whole blood |
2.3 |
2.27 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
5421-3 |
CD106 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD106 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5421-3 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD106 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; INCAM-110; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; Vascular cell adhesion molecule-1; VCAM1; VCAM-1; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
54210-0 |
Hepatitis B virus basal core promoter mutation |
Prid |
Ser |
Pt |
Nom |
Probe.amp.tar |
|
ACTIVE |
Hepatitis B virus basal core promoter mutation [Identifier] in Serum by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
54210-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HBV BCP Mut Ser NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; HBV; HBV BCP; HBV BCP Mut; Hep; Hep B; Hepatis; Hepatit; Hepatology; HepB; ID; Identity or presence; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Liver; Microbiology; Mut; Mutations; NAA+probe; NAAT; NASBA; Nominal; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Serum; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54211-8 |
Cortisol^24H post dose dexamethasone |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Moles/volume] in Serum or Plasma --24 hours post dose dexamethasone |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHAL |
|
54211-8 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 24h p DEX SerPl-sCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; 24h p DEX; After; c350; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Decadron; Dexameth; Dexone; F; Hexadrol; hydrocortisone; Level; p Dex; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.27 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
54212-6 |
Cortisol^3D post dose dexamethasone |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Moles/volume] in Serum or Plasma --3 days post dose dexamethasone |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHAL |
|
54212-6 |
|
|
|
|
Both |
|
|
|
0 |
Cortis 3D p Dex SerPl-sCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; 3D p Dex; After; c350; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Decadron; Dexameth; Dexone; F; Hexadrol; hydrocortisone; Level; p Dex; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.27 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
54213-4 |
Cortisol^4D post dose corticotropin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Moles/volume] in Serum or Plasma --4 days post dose corticotropin |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHAL |
|
54213-4 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 4D p Dex SerPl-sCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; 4D p Dex; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Cortrosyn; F; hydrocortisone; Level; p ACTH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tumor marker |
2.7 |
2.27 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
54214-2 |
Cortisol^5D post dose dexamethasone |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Moles/volume] in Serum or Plasma --5 days post dose dexamethasone |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHAL |
|
54214-2 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 5D p Dex SerPl-sCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; 5D p Dex; After; c350; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Decadron; Dexameth; Dexone; F; Hexadrol; hydrocortisone; Level; p Dex; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.27 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
54215-9 |
Cortisol^5H post dose corticotropin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Cortisol [Moles/volume] in Serum or Plasma --5 hours post dose corticotropin |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
CHAL |
|
54215-9 |
|
|
|
|
Observation |
|
|
|
0 |
Cortis 5h p Dex SerPl-sCnc |
|
|
|
N |
|
17-Hydroxycorticosterone; 5h p Dex; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Cortrosyn; F; hydrocortisone; Level; p ACTH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tumor marker |
2.7 |
2.27 |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
54216-7 |
Insulin-like growth factor binding protein 1^pre or post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin-like growth factor binding protein 1 [Mass/volume] in Serum or Plasma --pre or post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
CHAL |
|
54216-7 |
|
|
|
|
Observation |
|
|
|
0 |
IGF BP1 pre/p chal SerPl-mCnc |
|
|
|
N |
|
After; Before; Bind; CHEMISTRY.CHALLENGE TESTING; Fac; Fact; HUM; Humulin; i; IGF; IGF BP; IGF BP1; IGFBP; IGFBP1; IGFBP-1; IH7; Insul; Lente; Level; Mass concentration; NPH; p chal; Pl; Plasma; Plsm; Point in time; PR; pre/p chal; Prot; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente |
2.7 |
2.27 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
54217-5 |
Public health notifiable condition |
Prid |
XXX |
Pt |
Nom |
|
|
ACTIVE |
Public health notifiable condition |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CLIN |
|
54217-5 |
|
|
|
|
Observation |
|
|
|
0 |
PH notifiable condition |
|
|
|
N |
|
CLIN; Identity or presence; Misc; Miscellaneous; Nominal; Other; PH notifiable condition; Point in time; Random; Spec; To be specified in another part of the message; Unspecified |
2.56 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Changed answer list from "Normative" to "Preferred" to fit the current LOINC model. |
0 |
54218-3 |
Cells.CD3+CD4+/Cells.CD3+CD8+ |
NRto |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Blood |
|
MIN |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CELLMARK |
|
54218-3 |
|
|
|
|
Both |
|
|
|
0 |
CD3+CD4+ Cells/CD3+CD8+ Cll Bld |
|
|
|
N |
|
Blood; CD3 Cells; CD3+CD4+ Cells; CD3+CD8+ Cells; CD3+CD8+ Cll; CD3-CD4+; CD4+ T cells; CD8 T cells; Cell; CELL MARKERS; Cellularity; Helper T cells; Inducer T cells; L3T4; Leu2; Leu-2; Leu3; Leu-3; Leu4; Leu-4; Number ratio; Point in time; QNT; Quan; Quant; Quantitative; Random; Suppressor T cells; Suppressor/cytotoxic T cells; T3; T4; T-4; T4 helper/inducer cells; T8; T-8; T8 suppressor cells; Tsuppressor; W3/25; WB; Whole blood |
2.79 |
2.27 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
54219-1 |
Coagulation thrombin induced.factor substitution^immediately after 1:4 addition of normal plasma |
Time |
PPP |
Pt |
Qn |
Coag |
|
ACTIVE |
Thrombin time.factor substitution in Platelet poor plasma by Coagulation assay --immediately after 1:4 addition of normal plasma |
|
MIN |
DefinitionDescription |
|
|
s |
this means that if a patient is on argatroban, lepirudin or a thrombin inhibitor, then a provider can order this test and it should help the provider with the care/treatment of the patient. Ref Range Comments: Therapeutic ranges are: Lepirudin: 90-160 s Argatroban: 60-100 s Bivalirudin: 60-90 s |
|
|
|
|
|
COAG |
|
54219-1 |
|
Coag |
|
|
Observation |
|
|
|
0 |
TT imm 1:4 NP PPP |
|
|
|
N |
|
Clot; Clottable; Coag; Coagulation assay; Control; Fac; Fact; Hematology; Heme; i; imm 1:4 NP; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; TCT; Throm; Thrombin clotting time; Thrombin time; Tilt tube; TT |
2.73 |
2.27 |
|
|
|
|
|
|
|
s |
|
|
|
0 |
5422-1 |
CD107a |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD107a cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5422-1 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD107a WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; LAMP-1; Leukocytes; Lysosome-associated membrane-protein 1; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
54220-9 |
Immune response markers |
Imp |
XXX |
Pt |
Nar |
|
|
ACTIVE |
Immune response markers [Interpretation] in Specimen Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
54220-9 |
|
|
|
|
Observation |
|
|
|
0 |
Immune response markers Spec-Imp |
|
|
|
N |
|
CELL MARKERS; Imm; Impression; Impression/interpretation of study; Impressions; Imun; Imune; Interp; Interpretation; Misc; Miscellaneous; Narrative; Other; Point in time; Random; Report; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54221-7 |
Lymphoma markers |
Imp |
XXX |
Pt |
Nar |
|
|
ACTIVE |
Lymphoma markers [Interpretation] in Specimen Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
54221-7 |
|
|
|
|
Observation |
|
|
|
0 |
Lymphoma markers Spec-Imp |
|
|
|
N |
|
CELL MARKERS; Hematology; Heme; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Misc; Miscellaneous; Narrative; Other; Point in time; Random; Report; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54222-5 |
Lymphoma - acute screen markers |
Imp |
XXX |
Pt |
Nar |
|
|
ACTIVE |
Lymphoma - acute screen markers [Interpretation] in Specimen Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
54222-5 |
|
|
|
|
Observation |
|
|
|
0 |
Lymphoma - acute screen markers Spec-Imp |
|
|
|
N |
|
CELL MARKERS; Hematology; Heme; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Misc; Miscellaneous; Narrative; Other; Point in time; Random; Report; Scn; Scr; Scrn; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54223-3 |
Lymphoma - CLL screen markers |
Imp |
XXX |
Pt |
Nar |
|
|
ACTIVE |
Lymphoma - CLL screen markers [Interpretation] in Specimen Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
54223-3 |
|
|
|
|
Observation |
|
|
|
0 |
Lymphoma - CLL screen markers Spec-Imp |
|
|
|
N |
|
CELL MARKERS; Chronic lymphocytic leukemia; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Misc; Miscellaneous; Narrative; Other; Point in time; Random; Report; Scn; Scr; Scrn; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54224-1 |
Lymphoma - T-cell markers |
Imp |
XXX |
Pt |
Nar |
|
|
ACTIVE |
Lymphoma - T-cell markers [Interpretation] in Specimen Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
54224-1 |
|
|
|
|
Observation |
|
|
|
0 |
Lymphoma - T-cell markers Spec-Imp |
|
|
|
N |
|
Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Misc; Miscellaneous; Narrative; Other; Point in time; Random; Report; Spec; T cell; T prime; To be specified in another part of the message; UCHL-1; Unspecified |
2.69 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
54225-8 |
Immune response panel |
- |
XXX |
Pt |
- |
Flow cytometry |
|
ACTIVE |
Immune response panel - Specimen by Flow cytometry (FC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CELLMARK |
|
54225-8 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
Immune response Pnl Spec FC |
|
|
|
N |
|
CELL MARKERS; Dynamic; FC; Imm; Immune response Pnl; Imun; Imune; Misc; Miscellaneous; Other; Pan; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
54226-6 |
Lymphoma panel |
- |
XXX |
Pt |
- |
Flow cytometry |
|
ACTIVE |
Lymphoma panel - Specimen by Flow cytometry (FC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CELLMARK |
|
54226-6 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
Lymphoma Pnl Spec FC |
|
|
|
N |
|
CELL MARKERS; Dynamic; FC; Lymphoma Pnl; Misc; Miscellaneous; Other; Pan; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; Spec; To be specified in another part of the message; UniversalLabOrders; Unspecified |
2.73 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
54227-4 |
Lymphoma - acute screen panel |
- |
XXX |
Pt |
- |
Flow cytometry |
|
ACTIVE |
Lymphoma - acute screen panel - Specimen by Flow cytometry (FC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CELLMARK |
|
54227-4 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
Lymphoma - acute screen Pnl Spec FC |
|
|
|
N |
|
CELL MARKERS; Dynamic; FC; Lymphoma - acute screen Pnl; Misc; Miscellaneous; Other; Pan; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; Scn; Scr; Scrn; Spec; To be specified in another part of the message; UniversalLabOrders; Unspecified |
2.69 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
54228-2 |
Lymphoma - CLL screen panel |
- |
XXX |
Pt |
- |
Flow cytometry |
|
ACTIVE |
Lymphoma - CLL screen panel - Specimen by Flow cytometry (FC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CELLMARK |
|
54228-2 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
Lymphoma - CLL screen Pnl Spec FC |
|
|
|
N |
|
CELL MARKERS; Chronic lymphocytic leukemia; Dynamic; FC; Lymphoma - CLL screen Pnl; Misc; Miscellaneous; Other; Pan; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; Scn; Scr; Scrn; Spec; To be specified in another part of the message; UniversalLabOrders; Unspecified |
2.73 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
54229-0 |
Lymphoma - T-cell screen panel |
- |
XXX |
Pt |
- |
Flow cytometry |
|
ACTIVE |
Lymphoma - T-cell screen panel - Specimen by Flow cytometry (FC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CELLMARK |
|
54229-0 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
Lymphoma - T-cell screen Pnl Spec FC |
|
|
|
N |
|
CELL MARKERS; Dynamic; FC; Lymphoma - T-cell screen Pnl; Misc; Miscellaneous; Other; Pan; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; Scn; Scr; Scrn; Spec; T cell; T prime; To be specified in another part of the message; UCHL-1; UniversalLabOrders; Unspecified |
2.69 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |